1. Signaling Pathways
  2. GPCR/G Protein
  3. Oxytocin Receptor

Oxytocin Receptor

The oxytocin receptor belongs to the G-protein-coupled seven-transmembrane receptor superfamily. Its main physiological role is regulating the contraction of uterine smooth muscle at parturition and the ejection of milk from the lactating breast. The oxytocin receptors are activated in response to binding oxytocin and a similar nonapeptide, vasopressin. Oxytocin receptor triggers Gi or Gq protein-mediated signaling cascades leading to the regulation of a variety of neuroendocrine and cognitive functions.

Oxytocin is a nonapeptide of the neurohypophyseal protein family that binds specifically to the oxytocin receptor to produce a multitude of central and peripheral physiological responses. In vivo, oxytocin acts as a paracrine and/or autocrine mediator of multiple biological effects. These effects are exerted primarily through interactions with G-protein-coupled oxytocin/vasopressin receptors, which, via Gq and Gi, stimulate phospholipase C-mediated hydrolysis of phosphoinositides.

Oxytocin Receptor Related Products (19):

Cat. No. Product Name Effect Purity
  • HY-17571A
    Oxytocin acetate
    Agonist ≥99.0%
    Oxytocin acetate is a pleiotropic, hypothalamic peptide known for facilitating parturition, lactation, and prosocial behaviors. Oxytocin acetate can function as a stress-coping molecule with anti-inflammatory, antioxidant, and protective effects especially in the face of adversity or trauma.
  • HY-108677
    L-368,899 hydrochloride
    Antagonist 98.61%
    L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent.
  • HY-17572A
    Atosiban acetate
    Antagonist 99.56%
    Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.
  • HY-124733A
    LIT-001
    Agonist 98.52%
    LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism.
  • HY-17573
    Carbetocin
    Agonist 99.49%
    Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS.
  • HY-14778
    Retosiban
    Antagonist 98.97%
    Retosiban (GSK221149A) is a potent and selective oxytocin antagonist with a Ki of 0.65 nM.
  • HY-15010
    L-371,257
    Antagonist ≥99.0%
    L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of oxytocin receptor (pA2=8.4) with high affinity at both the oxytocin receptor (Ki=19 nM) and vasopressin V1a receptor (Ki=3.7 nM).
  • HY-17572
    Atosiban
    Antagonist 99.09%
    Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.
  • HY-17573A
    Carbetocin acetate
    Agonist 99.81%
    Carbetocin acetate, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a Ki of 7.1 nM. Carbetocin acetate has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (Ki=1.17 μM). Carbetocin acetate has the potential for postpartum hemorrhage research. Carbetocin acetate can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS.
  • HY-15015
    OT-R antagonist 1
    Antagonist ≥98.0%
    OT-R antagonist 1 is a new potent and selective nonpeptide low molecular weight OT-R antagonist.
  • HY-15015A
    OT-R antagonist 2
    Antagonist 99.74%
    OT-R antagonist 2 is a nonpeptide low molecular weight OT-R antagonist.
  • HY-128351
    SHR1653
    Antagonist
    SHR1653 is a highly potent, selective and brain penetrated oxytocin receptor (OTR) antagonist, with an IC50 of 15 nM for hOTR.
  • HY-105018
    Epelsiban
    Antagonist
    Epelsiban (GSK 557296) is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pKi of 9.9 for human oxytocin receptor.
  • HY-103649
    OT antagonist 3
    Antagonist
    OT antagonist 3 is an oxytocin (OT) antagonist extracted from patent WO2007017752A1.
  • HY-P3217
    [Asp5]-Oxytocin
    Agonist
    [Asp5]-Oxytocin is the first 5-position neurohypophyseal hormone analogue possessing significant biological activity.
  • HY-124733
    LIT-001 free base
    Agonist
    LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 free base improves social interaction in a mouse model of autism.
  • HY-103650
    OT antagonist 1
    Antagonist
    OT antagonist 1 (Compound 4) is a potent, selective Oxytocin antagonist with a Ki of 50 nM.
  • HY-15011
    L-372662
    Antagonist 98.70%
    L-372662 is a potent and orally active non-peptide oxytocin antagonist with a Ki value of 4.8. The Kd value of L-372662 for wild-type hOTR and [A318G]OTR is 5.8 nM and 73 nM. L-372662 shows selectivity to OTR:V1aR.
  • HY-103651
    OT antagonist 1 demethyl derivative
    Antagonist
    OT antagonist 1 demethyl derivative is the demethyl derivative of OT antagonist 1. OT antagonist 1 (Compound 4) is a potent, selective Oxytocin antagonist with a Ki of 50 nM.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.